Dr Jeff Holst
Position:
- Head, Origins of Cancer Laboratory, Centenary Institute
Credentials:
- Dr
Websites:
Biography:
Dr Holst completed his PhD in Immunology in 2003 at St Vincent’s Hospital Centre for Immunology in Sydney, before undertaking postdoctoral studies at St Jude Children’s Research Hospital in the USA.
He has a strong reputation for research excellence and implementation of new techniques, including mouse models, flow cytometry, and gene transfer. His most significant research contribution was published in Nature Immunology in 2008, and resulted in the receipt of the inaugural Research Australia Discovery Award.
After devising a ground-breaking new technique for expressing T-cell receptors in mice, he returned to Australia in 2006, to focus on cancer research with funding from the Cancer Institute NSW, the NHMRC, Cancer Council NSW, PCFA and the National Breast Cancer Foundation.
Dr Holst is currently Associate Faculty and Head of the Origins of Cancer Lab at the Centenary Institute, where his work is focussed on the role of nutrient transporters in prostate and breast cancer.
Best publications:
Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minhas V, Lehman ML, Hendy SC, Buchanan G, Nelson CC, Rasko JEJ and Holst J. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport in prostate cancer progression. Cancer Research 71(24):7525-36, 2011.
Holst J, Watson S, Lord M, Eamegdool S, Bax D, Nivison–Smith L, Kondyurin A, Ma L, Oberhauser A, Weiss A and Rasko JEJ. Substrate elasticity provides mechanical signals for expansion of hemopoietic stem and progenitor cells. Nature Biotechnology 28(10):1123-8, 2010.
Tiffen JC, Bailey CG, Ng C, Rasko JEJ and Holst, J. Luciferase expression does not affect tumor cell growth in vitro or in vivo. Molecular Cancer 9:299, 2010.
Holst J, Wang H, Durick Eder K, Workman CJ, Boyd KL, Baquet Z, Singh H, Forbes K, Chruscinski A, Smeyne R, van Oers NSC, Utz PJ & Vignali DAA. Scalable signaling mediated by T cell antigen receptor–CD3 ITAM ensures effective negative selection and prevents autoimmunity. Nature Immunology 9, 658-666, 2008.
Holst J, Vignali K, Burton AR, Vignali DAAV. Rapid analysis of T cell selection in vivo using T cell receptor retrogenic mice. Nature Methods 3(3), 191-197, 2006.
Amino acid transport, mTORC1 signaling.
